期刊
PEDIATRIC BLOOD & CANCER
卷 55, 期 7, 页码 1396-1398出版社
WILEY
DOI: 10.1002/pbc.22766
关键词
angiogenesis; new agents; vascular malformations
Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which his been used extensively in children following solid organ transplantation has been demonstrated to have anti angiogenic activity in pre clinical models Limited experience suggests that it may have application to the treatment of vascular lesions We describe our experience with a 1 year old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0 1 mg/kg/day) This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions Pediatr Blood Cancer 2010 55 1396-1398 (C) 2010 Wiley Liss Inc
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据